Table 2.

Selected studies evaluating the safety and efficacy of CAR T-cell therapy in SCNSL

Study	Product	N	Response, %	Survival, mo	CRS, %	Neurotoxicity, %
TRANSCEND105	Liso-cel	7∗	ORR, 50 CR, 50	NR	Any grade, 29 Grade ≥3, 0	Any grade, 29 Grade ≥3, 29
NCT0460848793	Axi-cel	9†	ORR, 78 CR, 67	mPFS, 11.5‡	Any grade, 88 Grade ≥3, 0	Any grade, 50 Grade ≥3, 37.5
Retrospective study106	Axi-cel	17§	ORR, 59 CR, NR	6-month EFS from infusion, 50%	Any grade, 93 Grade ≥3, 13	Any grade, 87 Grade ≥3, 33
Retrospective study92	Tisa-cel	8	ORR, 50 CR, 25	NR	Any grade, 87 Grade ≥3, 0	Any grade, 37 Grade ≥3, 0
Retrospective study107	Tisa-cel, 57% Axi-cel, 43%	7	ORR, 86 CR, 86	mPFS, 2.8 mOS, 4.3	Any grade, 57 Grade ≥3, 14	Any grade, 43 Grade ≥3, 14
Retrospective study108	Axi-cel	5	ORR, 80‖ CR, 60	mPFS, 4.5 mOS, 5.2	Any grade, 40 Grade ≥3, 0	Any grade, 40 Grade ≥3, 40
Retrospective study109	Costimulatory domain 4-1BB, 80% CD28, 20%	10	ORR, 70¶ CR, 20	mPFS (systemic), 3 mPFS (CNS), not reached	Any grade, 100 Grade ≥3, 10	Any grade, 60 Grade ≥3, 30

EFS, event-free survival; mPFS, median PFS; mOS, median OS; NR, not reported.

^∗Six patients evaluable for response.

^†PCNSL, 67% and SCNSL, 33%.

^‡Ongoing accrual and follow-up.

^§Fifteen patients evaluable for response.

^‖One patient with stable disease.

^¶Three patients with stable disease.